Cargando…
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
BACKGROUND: Interstitial lung disease (ILD) frequently complicates systemic autoimmune disorders resulting in considerable morbidity and mortality. The connective tissue diseases (CTDs) most frequently resulting in ILD include: systemic sclerosis, idiopathic inflammatory myositis (including dermatom...
Autores principales: | Saunders, Peter, Tsipouri, Vicky, Keir, Gregory J., Ashby, Deborah, Flather, Marcus D., Parfrey, Helen, Babalis, Daphne, Renzoni, Elisabetta A., Denton, Christopher P., Wells, Athol U., Maher, Toby M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471887/ https://www.ncbi.nlm.nih.gov/pubmed/28619061 http://dx.doi.org/10.1186/s13063-017-2016-2 |
Ejemplares similares
-
The role of precision medicine in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022) -
The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019) -
Récit écrit, récit filmique /
por: Vanoye, Francis
Publicado: (1998) -
Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial
por: Visca, Dina, et al.
Publicado: (2017) -
Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease
por: Jacob, Joseph, et al.
Publicado: (2018)